|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||8.70 - 9.26|
|52 Week Range||3.88 - 11.73|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shares in Curaleaf, one of America's largest cannabis companies, are surging on the announcement that the company is acquiring the leading West Coast cannabis oil manufacturer, Cura Partners, in an all-stock deal valued at about $950 million. Yahoo Finance's Zack Guzman, Alexis Keenan & Sibile Marcellus discuss with Curaleaf CEO Joseph Lusardi.
What's behind Curaleaf’s Gains on May 6?(Continued from Prior Part)Analysts’ recommendationsOf the seven analysts following Curaleaf Holdings (CURA) (CURLF), three analysts have given the stock a “strong buy” rating, while four analysts are
What's behind Curaleaf’s Gains on May 6?The announcementOn May 6, Curaleaf Holdings (CURA) (CURLF) announced that it signed a definitive agreement with Ohio Grown Therapies that grants it the option to acquire Ohio Grown Therapies’ licenses and
Curaleaf entered into a definitive agreement that grants it an option to buy Ohio Grown Therapies medical cannabis cultivation and processing licenses. Curaleaf said it can complete the acquisition of Ohio Grown Therapies' licenses and the lease in the second half of 2019.
The latest move by Curaleaf (CURLF) sets the U.S. cannabis company as not only a domestic leader, but also a global leader in the cannabis sector. The company will now have a market valuation in the $6 billion range with the revenue base similar to the Canadian players without the massive market valuations. The multi-state operators (MSOs) remain of the best ways to play cannabis growth in 2019.Big DealCuraleaf bought the state-regulated cannabis business from Cura Partners for $949 million. The partners own the Select brand that is a leading West Coast wholesale brand with 2018 revenues of $117 million.The deal involves Curaleaf issuing 95.6 million at a closing price of C$13.30. The deal includes an additional earn-out of up to $200 million for exceeding 2020 revenue targets in the wholesale extract business and Select-branded retail extract sales.The Select brand is a market leader in states like California, Oregon and Arizona. When combined with the Acres Cannabis acquisition, Curaleaf will have the top market share in Nevada. Maybe most importantly, the domestic cannabis company will have an oil market share of at least 25% in key states like California and Oregon.The combined company will have 1,000,000 square feet of cultivation space with 11 cultivation facilities, 44 retail locations in operation and 15 states with THC sales by the end of 2019. Maybe even more importantly going forward is the 1,000+ retail stores and 900+ wholesale dispensary accounts selling products from Curaleaf brands.Market LeaderThe interesting part of the story is that the new Curaleaf had pro-forma 2018 revenues that topped $200 million with nearly $75 million in the December quarter. The amount actually tops the $62 million produced by Canopy Growth (CGC) in the December quarter while the later gets all of the headlines due to the NYSE listing and large investment from Constellation Brands (STZ).According to Curaleaf estimates, the company now has double the trailing revenues of any other player in the key U.S. cannabis market. Some other MSOs have big 2020 targets so looking at past revenues is important, but the key is where the company goes from here as plenty of state markets are just now opening up.Source: Curaleaf presentation Curaleaf alone had already forecasted that 2019 revenues would reach $400 million with free cash flow of $100 million. The company is very busy expanding on the East Coast with new operations in Florida, Maryland and New York and states like Ohio and Pennsylvania in the works.TakeawayThe key investor takeaway is that the way to play the cannabis market remains these U.S. MSOs that are expanding operations and acquiring business in the largest global market. Stocks like Curaleaf have major catalysts such as uplisting on major exchanges and the federal legalization of cannabis in the U.S.A company like Curaleaf is a potential acquisition target by major players either in Canada or beverage and tobacco companies from the U.S. and potentially around the globe. All of these companies will want access to a U.S. cannabis market estimated by Cowen to reach $80 billion by 2030. Curaleaf is now in the drivers seat without the lofty valuation.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. Disclosure: The author has no positions in Curaleaf stock.Read more on Curaleaf : * Curaleaf (CURLF): A Multi-State Cannabis Stock Play * This Medical Cannabis Player Has Big Ambitions, But Will It Succeed? More recent articles from Smarter Analyst: * Love or Hate Aurora Cannabis (ACB) Stock, That’s Where the Money Is * Micron's (MU) Tech Roadmap Highlights Flattening Cost Curve, Says Analyst; Reiterates Neutral on the Stock * Time to Cash Out on Cannabis Stock Canopy Growth (CGC) * GW Pharmaceuticals (GWPH) Stock Could Run Much Higher Over Time
Curaleaf’s deal to buy Cura Partners stemmed from a desire to specifically acquire the most popular cannabis oil brand in California, Nevada and Oregon.
Curaleaf Holdings Inc. shares soared Wednesday to lead the cannabis sector higher, after the company announced it is acquiring Cura Partners, the parent of the Select brand, in an all-stock deal valued at C$1.27 billion, or about $949 million.
It doesn't have the star power of former politicians on its board of directors or flashy videos by Hollywood directors, but Cresco Labs Inc. The company prefers to let its numbers speak and eschews the flash of other cannabis companies. The company recently reported its earnings and along with its results, Cresco presented a slideshow of statistics.
Curaleaf will issue to Cura shareholders around 95.6 million subordinated voting shares. In this way after the acquisition, Cura shareholders will own around 16 percent of Curaleaf on a fully-diluted basis. Cura shareholders will also be eligible to receive an earn-out of up to $200 million from the issuance of additional shares, subject to Curaleaf exceeding certain 2020 revenue targets.
Curaleaf Holdings is acquiring the maker of a leading West Coast cannabis brand in Cura Partners' Select for nearly $950 million.
announced it agreed to purchase Cura Partners, owners of the Select cannabis brand, for C$1.27 billion, or $948.8 million. The acquisition includes Select's manufacturing, processing, distribution, marketing and retailing operations and all adult-use cannabis products marketed under the Select brand name. "The transformational acquisition of Cura and the Select brand is another step in our journey to create the most accessible cannabis brands in the U.S.," said Joseph Lusardi, CEO of Curaleaf.
Curaleaf Holdings Inc. said Wednesday it has signed a definitive agreement to acquire Cura Partners Inc., the parent of the Select brand, in an all-stock deal valued at C$1.27 billion ($948.8 million). Wakefield, Mass.-based Curaleaf said the deal includes Portland, Ore.-based Select's manufacturing, processing, distribution, marketing and retailing operations and all adult-use cannabis products marketed under the Select brand name, including its intellectual property. Select products are sold at more than 900 retailers in states that have legalized cannabis. To finance the deal, Curaleaf will issue about 95.6 million subordinated voting shares, which are worth C$1.27 billion based on the stock's closing price of C$13.30 on April 30. The stock trades on the CSE as well as on the U.S. over-the-counter market. The deal is expected to close in 2019. It constitutes a 'related party transaction,' because Curaleaf chairman Boris Jordan has an interest in the deal, Curaleaf said in a statement. "The terms of the proposed transaction were negotiated by management and advisors under guidance of, and unanimously recommended for approval by, a committee composed of members of the Board of Directors of Curaleaf free from any conflict of interest with respect to the proposed transaction," said the statement. The committee relied on a fairness opinion from Beacon Securities Ltd. to ensure it is paying a fair price. The founder of the Select brand, Cameron Forni, will join Curaleaf as president of Select, which he started in 2015. Curaleaf U.S.-listed shares were not active premarket, but have gained 107% in 2019 to date, while the S&P 500 has gained 17.5%.
This newly-introduced cannabis exchange-traded fund is holding 32 pot stocks -- but it's not nearly as diversified as it sounds.
Medmen Enterprises Inc (OTC: MMNFF) has licenses for 82 stores in four states — California, Florida, Nevada and New York — Vahan Ajamian, the company's managing director of analyst relations, said in a presentation. Echoing a common theme at the Cannabis Capital Conference, Ajamian said California, where MedMen has 10 stores and is building out two more, is the ultimate prize for the cannabis industry as a retail trendsetter.
"Thirty seconds for the market to open," a Toronto Stock Exchange representative said as the crowd started to clap, cheer and celebrate. It was the anniversary of the Evolve Marijuana ETF (TSX:SEED)(OTC:EVVLF) and they were celebrating being the best-performing equity ETF on the TSX in the last year.
Horizons is the company behind the Horizons Marijuana Life Sciences Index ETF (TSX: HMMJ)(OTC: HMLSF), which is one of the world's largest cannabis ETFs. “HMUS will be the first ETF in the world that is solely focused on providing exposure to companies with significant business activities in, or significant exposure to, the United States marijuana or hemp industries,” according to a statement.
Marijuana stocks have become much more accepted by mainstream investors in the past few years. However, just because investing in cannabis is getting more common doesn't mean it's not dangerous territory for investors.A parade of marijuana stocks has listed on major U.S. exchanges since the beginning of 2018. In addition, a growing number of Wall Street analysts are now covering marijuana stocks. Cannabis investors are no longer automatically smirked at. Unfortunately, there are still plenty of dangers lurking in the cannabis market. The Dangers Of OTC StocksMarijuana stocks like Canopy Growth Corp (NYSE: CGC), Tilray (NASDAQ: TLRY) and Aurora Cannabis (NYSE: ACB) have gained legitimacy in the past year by transitioning to the NYSE and Nasdaq exchanges.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 AI Stocks to Watch with Strong Long-Term Narratives At the same time, U.S. multi-state cannabis operators like Curaleaf Holdings (OTC: CURL), Medmen Enterprises (OTC: MMNFF) and Green Thumb Industries (OTC: GTBIF) are currently relegated to trading on the OTC market. Since these companies are technically running U.S. businesses that contravene federal laws, they will likely stay on the OTC market for the time being.OTC stocks have a somewhat poor reputation among average investors. Many OTC stocks trade for under $1 per share, and it's common for OTC stocks to provide little financial information to investors. The information these companies do provide is often unreliable.As a result, it can be difficult for investors to get a clear picture of what's going on at companies with OTC stocks. Essentially, all companies need to do to list on the OTC is fill out a request form.Most cannabis stocks are far from the typical, sketchy, OTC-listed stock. However, that doesn't mean all the dangers mentioned above don't still apply to them. Medmen's Fake NewsSince information about OTC-listed stocks can be difficult to obtain, greedy traders and greedy companies can take advantage of the situation. Companies listed on the OTC markets are notorious for carrying out "pump-and-dump" schemes. Those schemes involve companies or third parties flooding message boards and social media platforms with fake news about a stock to drive its price higher. These companies or third parties will then cash out at the peak, and other buyers of the stock will get burned.Pump-and-dump schemes are technically illegal. But so is driving over the speed limit, and plenty of people still get away with it. And if you think these types of stock-promotion schemes aren't used to pump and dump reputable cannabis stocks, you're wrong.Seven analysts are currently covering Medmen (OTC: MMNFF), and six of the seven analysts recommend that investors buy MMNFF stock. Yet just last month, Medmen admitted to using an agreement with a company called Winning Media to promote MMNFF stock. In a press release, Medmen said it "disclaims any potentially exaggerated or misleading statements contained in the materials" distributed online by Winning Media. But at that point, the damage to the owners of MMNFF stock may have already been done.Medmen will likely be particularly careful in the future about the types of public relations deals that it makes. However, given how thinly-traded the OTC market is, stock promoters don't need companies' permission to promote stocks. The promoters can simply take a position in a stock, spread fake news online and cash out. The company may be none the wiser. Avoiding Pump-and-Dump Cannabis StocksFortunately for cannabis investors, there are ways to avoid being misled by promoters. According to Todd Fromer, the managing partner of KCSA Strategic Communications, common sense can go a long way for cannabis-stock investors. Fromer says investors can watch for certain red flags when reading about marijuana stocks online.First, only trust reputable news sources. A good rule of thumb is to consider whether or not you've heard of the website before. For example, a news article on Bloomberg or CNBC is fine. An article on GetRichQuickWithPennyStocks.com may not be.Second, look for disclosures indicating the article is an advertisement. Finally, use common sense to identify stories that are too good to be true. Actual journalists will almost never make claims like "1000% upside" or "guaranteed profits.""As the cannabis sector continues to gain momentum it's critical that both investors and company management remain vigilant," Fromer recently wrote.Marijuana stocks have taken major strides in recent quarters towards leaving their shady past behind. Unfortunately, some U.S. cannabis companies still have a long way to go. In the meantime, just because cannabis stocks are getting much more mainstream media coverage doesn't mean investors can let their guard down. Don't believe everything you read about marijuana stocks.As of this writing, Wayne Duggan did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Best Dividend Stocks to Buy for Every Investor * 7 Catalysts That Will Send Marijuana Stocks Soaring in 2019 * 8 Risky Stocks to Watch as Earnings Season Kicks Off Compare Brokers The post Don't Believe Everything You Read About Marijuana Stocks appeared first on InvestorPlace.
Is There More Upside to Curaleaf Holdings’ Stock Price?(Continued from Prior Part)Analysts’ recommendationsAmong the six analysts that follow Curaleaf Holdings (CURA) (CURLF), three recommended a “strong buy,” while three recommended a
Is There More Upside to Curaleaf Holdings’ Stock Price?Stock performance Curaleaf Holdings (CURA) (CURLF) has started 2019 on a stronger note. As of April 9, the company’s stock price has increased 83.0% since the beginning of the year. In
Planet 13 and Wayland Group Posted Strong Performance Last Week(Continued from Prior Part)Stock performance Cannabis stocks were mixed last week. Of the seven companies considered for our analysis in this article, three have given positive returns,
Planet 13’s Superstore Earned Revenues of $5.5 Million in MarchRevenue growth Planet 13 Holdings (PLNHF) (PLTH) announced today that its Las Vegas Cannabis Entertainment Complex, also called the Superstore, posted revenue of $5.5 million in March.
The positive response to China trade negotiation headlines is becoming too routine and is starting to generate more of a "sell the news" response. While there is still optimism about positive progress, the headlines have been non-specific and market players are more skeptical of the quick moves on the news.